buyWeak
Kevin C Tang bought $86k of TCRR
owner at TCR2 THERAPEUTICS INC.. 50,000 shares at an average of $1.72, traded May 25, 2023, filed May 30, 2023.
Conviction score
31Value
$86k
50,000 shares
Holdings after
4,394,800
+1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +9Trade size$86k at market
- 0Relative to holdingsHoldings up 1.2%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying4 buys in 90 days
- +10Track recordMedian 6-month excess return +10% over 4 past buys
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-23-033041, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 25, 2023 | POpen-market purchase Common Stockindirect: By LP | +50,000 | $1.72 | $86k | 4,394,800 | May 30, 2023 |
Related signals
Other insiders at TCR2 THERAPEUTICS INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | TCR2 THERAPEUTICS INC. | Mpm Asset Management LLC owner | $132k 70,170 shares | -19% | |
| 39Weak | TCR2 THERAPEUTICS INC. | Ansbert Gadicke director, owner | $132k 70,170 shares | -19% | |
| 31Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $88k 44,948 shares | +1% | |
| 33Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $164k 83,988 shares | +2% | |
| 39Weak | TCRRbuy TCR2 THERAPEUTICS INC. | Kevin C Tang owner | $548k 289,577 shares | +7% | |
| 15Weak | TCR2 THERAPEUTICS INC. | Alfonso Quintas Cardama Chief Medical Officer | $15k 13,799 shares | -11% | |
| 15Weak | TCR2 THERAPEUTICS INC. | Angela Justice Chief People Officer | $9,448 8,620 shares | -15% | |
| 31Weak | TCR2 THERAPEUTICS INC. | Garry E Menzel President and CEO | $35k 31,938 shares | -19% | |
| 15Weak | TCR2 THERAPEUTICS INC. | Peter Olagunju Chief Technical Officer | $5,299 4,830 shares | -17% | |
| 10Weak | TCR2 THERAPEUTICS INC. | Alfonso Quintas Cardama Chief Medical Officer | $10k 7,942 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.